WILSON JAMES N sold $883K of CORT (indirect holdings)

WILSON JAMES N sold 10,000 indirectly-held shares of CORCEPT THERAPEUTICS INC (CORT) at an average of $88.30 ($86.78–$89.49, $0.88M total) across 4 trades on 2026-07-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · WILSON JAMES N
Published Jul 17, 2026, 10:38 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 17, 2026, 10:41 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CORT
Neutral
high confidence
Mentioned
$CORT
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CORTNeutralLow
01

Why it matters

Traders may monitor insider activity for sentiment, but 10b5-1 sales are typically less informative about near-term fundamentals. Without accompanying company news, the signal is weak.

02

Market read

A routine insider sale worth ~$883K was disclosed, with no new company-specific catalyst.

03

What to watch

The article provides only the sale details; it does not include any offsetting buys, changes in other holdings, or new company catalysts that would justify a stronger trading view.

Relevance 4/10Novelty 3/10Timing: Filed on 2026-07-17, reporting sales executed on 2026-07-15.

Background

The article is a SEC Form 4 insider transaction disclosure for Corcept Therapeutics, reported as an indirect open-market sale by a director under a pre-arranged 10b5-1 plan.

Company-level read

Ticker impact

$CORTNeutralHigh confidence
Context

Corcept Therapeutics director Wilson James N sold about 10,000 shares in an open-market transaction under a 10b5-1 plan, worth ~$883K.

Expected impact

Low likelihood of sustained price impact; any reaction is likely brief and sentiment-driven.

Evidence & confidence

The filing is a routine Form 4 open-market sale under a pre-arranged 10b5-1 plan, with no new operational, financial, or regulatory information disclosed.

Market effects

Minimal. Insider sale in a single name does not imply sector-wide changes.

None indicated.

None indicated.

Counterpoint

Because the sale is under a 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations.

Key entities

  • CORCEPT THERAPEUTICS INC

    Company whose director insider sale is disclosed on Form 4.

  • WILSON JAMES N

    Director who sold shares indirectly under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CORTMedAI 8/10

Corcept reports 8-year response in vulvar cancer case study

Corcept Therapeutics (CORT) reported a case study in ESMO Rare Cancers showing an 8-year response to relacorilant plus nab-paclitaxel in a metastatic vulvar cancer patient. The company noted this is a single case and not representative of the broader population. Relacorilant is FDA-approved for platinum-resistant ovarian cancer but not vulvar cancer. Corcept is developing the drug for other cancer types.

$CORTMed

Corcept Therapeutics Inc (CORT) (Q3 2026) Earnings Call Highlights: Revenue Surges 64%

Corcept Therapeutics (CORT) reported Q3 2026 revenue of $91M, up 64% YoY, driven by Lifyorli's growth. Management expects Lifyorli to move earlier in treatment sequences and sees potential for $1B in revenue. The company reiterated its 2026 guidance of $1.1B-$1.2B, citing strong performance in endocrinology and oncology. CEO Belanoff discussed upcoming clinical trials and potential combinations for Lifyorli.

$CORTMedAI 8/10

Corcept Therapeutics Q3 Earnings Call Highlights

Corcept Therapeutics (CORT) reported positive results from its BELLA Phase 2 trial, with relacorilant showing median progression-free survival of 7.2 months and a 59% response rate. The FDA is set to decide on relacorilant's application for Cushing's syndrome by December 17. Corcept also outlined ongoing trials for relacorilant in various cancers and miricorilant in MASH, with results expected by 2027. The company plans to initiate a Phase 3 ALS study next year.